news
Antibiotic resistance poorly communicated and widely misunderstood
31 July 2015 | By Victoria White
People in the UK have little awareness of what ‘antibiotic resistance’ means, according to new research commissioned by the Wellcome Trust...
List view / Grid view
Drug delivery
news
Phase I clinical trial of oral formulation of MGB-BP-3 for treatment of Clostridium Difficile infections begins
21 July 2015 | By Victoria White
The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3...
news
FDA QIDP designation for Motif’s iclaprim for HABP
20 July 2015 | By Victoria White
The US FDA has designated Motif Bio's iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)...
news
Scientists find new streptococcus variant causing severe infections
15 July 2015 | By Victoria White
Scientists have discovered a new subtype of emm89 streptococcus that has contributed to a rise in disease cases in the UK over the last 17 years...
article
Issue #3 2015 – Digital edition
In Issue #3 2015: Regulatory Insight, Microfluidics, PCR in-depth focus, Drug Delivery, Content Uniformity, HPLC, Microbiology in-depth focus, NMR, PAT and much more...
article
Polyelectrolyte complexes as nanoparticulate drug delivery systems
3 July 2015 | By Anita Umerska, University of Anger and Lidia Tajber, Trinity College Dublin
Polyelectrolyte complexes at the nanoscale (polyelectrolyte complex nanoparticles; PECNs) can be harnessed as drug delivery systems for a range of low molecular weight drugs as well as peptides and proteins. The mild method of manufacture of PECNs results in the protection of the loaded bioactive and the choice of polyions…
news
UK leads Europe in antimicrobial point-of-care diagnostics research
2 July 2015 | By Victoria White
The UK takes the lead position when it comes to patent filings for antimicrobial point-of-care diagnostics in Europe...
news
Repeated courses of antibiotics may alter a child’s development
A study by NYU Langone Medical Centre researchers adds to growing evidence that multiple courses of commonly used antibiotics may have a significant impact on children's development.
news
Re-energising antibiotics in the war against resistance
24 June 2015 | By Victoria White
Researchers have pinpointed a critical differentiator that separates the effects of bactericidal and bacteriostatic antibiotics: cellular respiration...
news
Bristol-Myers Squibb will win big with melanoma combination immunotherapy
23 June 2015 | By Victoria White
Data presented at ASCO 2015 suggests that the Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape...
news
Azithromycin proves strikingly effective against drug-resistant superbugs
18 June 2015 | By Victoria White
A new study shows that the antibiotic azithromycin, often prescribed to cure common infections, kills many multidrug-resistant bacteria very effectively...
news
Blaze Bioscience announces open enrollment for Phase 1 clinical trial of Tumour Paint BLZ-100 in children with brain cancer
4 June 2015 | By Victoria White
Blaze Bioscience has announced open enrollment for the first clinical study of Tumour Paint BLZ-100 in children with brain cancer...
news
Syrris launches novel quantum dot synthesis system
2 June 2015 | By kdm communications
Syrris, a world leader in chemistry product innovation, has launched the Atlas Nanoparticle System for the automated synthesis of quantum dots...
news
Amgen and Roche collaborate on cancer immunotherapy study with talimogene laherparepvec and atezolizumab
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
news
First patient dosed in the Phase 2 study of SER-109 in recurrent Clostridium difficile infection
28 May 2015 | By Victoria White
Seres Therapeutics has enrolled and dosed the first patient in its Phase 2 clinical study of SER-109 in recurrent CDI in adults...
